Management of Axial Spondyloarthritis – Insights into Upadacitinib

References

• Spinelli FR, Colbert RA, Gadina M. JAK1: number one in the family; number one in inflammation? Rheumatology. 2021;60(Suppl 2):ii3–ii10. doi:10.1093/rheumatology/keab024
   PubMed Web of Science ®Google Scholar
• Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–875. doi:10.1136/annrheumdis-2020-219012
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;1–13. doi:10.1038/s41584-021-00711-1
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–368. doi:10.1002/art.1780270401
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783. Erratum in: Ann Rheum Dis 2019 Jun; 78(6): e59. doi:10.1136/ard.2009.108233
   PubMed Web of Science ®Google Scholar
• Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. doi:10.1136/annrheumdis-2020-218398
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK,…; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. doi:10.1016/S0140-6736(18)31115-2
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. doi:10.1016/S0140-6736(18)31116-4
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239. doi:10.1056/NEJMoa2022516
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. [ Erratum in: RMD Open 2021 Nov; 7 (3)]. doi:10.1136/rmdopen-2021-001838
   PubMed Web of Science ®Google Scholar
• White JPE, Coates LC. JAK1 selective inhibitors for the treatment of spondyloarthropathies. Rheumatology. 2021;60(Suppl 2):ii39–ii44. doi:10.1093/rheumatology/keaa815
   PubMed Web of Science ®Google Scholar
• Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology. 2021;60(Supple2):ii45–ii51. doi:10.1093/rheumatology/keaa896
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology. 2020;158(8):2123–2138.e8. doi:10.1053/j.gastro.2020.01.047
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170. doi:10.1016/S2468-1253(21)00377-0
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108–2117. doi:10.1016/S0140-6736(19)32534-6
   PubMed Web of Science ®Google Scholar
• Deodhar A, van der Heijde D, Sieper J, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and Open-label extension. Arthritis Rheumatol. 2022;74(1):70–80. doi:10.1002/art.41911
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Maksymowych WP, et al. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022;8(2):e002280. doi:10.1136/rmdopen-2022-002280
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. 2022. Ann Rheum Dis. annrheumdis-2022–222608.
   Google Scholar
• Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of Adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(3):R117. doi:10.1186/ar3054
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Tirri E, Giardino AM, et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178. doi:10.3390/jcm11144178
   PubMed Web of Science ®Google Scholar
• Dougados M, Wei JC, Landewé R, et al.; COAST-V and COAST-W Study Groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–185. Erratum in: Ann Rheum Dis 2020 Jun; 79(6): e75. doi:10.1136/annrheumdis-2019-216118
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a Phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347. doi:10.1136/annrheumdis-2016-210322
   PubMed Web of Science ®Google Scholar
• Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a Phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004–1013. doi:10.1136/annrheumdis-2020-219601
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–2387. doi:10.1016/S0140-6736(18)32463-2
   PubMed Web of Science ®Google Scholar
• Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701–715. doi:10.1080/1744666X.2021.1925541
   PubMed Web of Science ®Google Scholar
• McInnes IB, Ostor AJK, Mease PJ, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022;8(1):e002049. doi:10.1136/rmdopen-2021-002049
   PubMed Web of Science ®Google Scholar
• Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369–379. doi:10.1016/S0140-6736(22)01212-0
   PubMed Web of Science ®Google Scholar
• AbbVie. Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Available from: https://news.abbvie.com/news/press-releases/abbvie-submits-applications-for-upadacitinib-rinvoq-in-non-radiographic-axial-spondyloarthritis-to-us-food-and-drug-administration-fda-and-european-medicines-agency-ema.htm. Accessed September 13, 2022.
   Google Scholar
• Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13–25. doi:10.1080/1744666X.2019.1544892
   PubMed Web of Science ®Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819–1828. doi:10.1007/s40265-019-01211-z
   PubMed Web of Science ®Google Scholar
• Winthrop K, Vargas JI, Drescher E, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022;8(1):e002110. doi:10.1136/rmdopen-2021-002110
   PubMed Web of Science ®Google Scholar
• Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.e12. doi:10.1053/j.gastro.2020.01.001
   PubMed Web of Science ®Google Scholar
• Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2021;73(5):779–788. doi:10.1002/art.41580
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Witte T. Januskinaseinhibitoren [Janus kinase inhibitors]. Z Rheumatol. 2022;81(2):94–99. doi:10.1007/s00393-021-01125-w
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed September 13, 2022.
   Google Scholar
• American College of Rheumatology. Search results for JAK FDA. Available from: https://www.rheumatology.org/Search/sb-bhvr/1/sb-logid/320106-kb5qq2gmlri6b81k?sb-search=JAK+FDA. Accessed September 13, 2022.
   Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Padda IS, Bhatt R, Parmar M. Upadacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi:10.1136/annrheumdis-2016-210770
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi:10.1136/annrheumdis-2020-217159
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Molnar C, Scherer A, Baraliakos X, et al.; Rheumatologists of the Swiss Clinical Quality Management Program. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77(1);63–69. doi:10.1136/annrheumdis-2017-211544
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Claudepierre P, de Hooge M, et al. Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Res Ther. 2021;23(1):43. doi:10.1186/s13075-021-02428-8
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Østergaard M, Landewé R, et al. Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). Rheumatology. 2021;3:keab543.
   Google Scholar
• Braun J, Kiltz U, Baraliakos X. Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. Ann Rheum Dis. 2022;81(1):11–14. doi:10.1136/annrheumdis-2021-221406
   PubMed Web of Science ®Google Scholar
• Ramiro S, van Tubergen A, van der Heijde D, et al. Brief report: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective follow up of patients with ankylosing spondylitis. Arthritis Rheumatol. 2014;66(10):2773–2779. doi:10.1002/art.38775
   PubMed Web of Science ®Google Scholar
• Hammitzsch A, Lorenz G, Moog P. Impact of janus kinase inhibition on the treatment of axial spondyloarthropathies. Front Immunol. 2020;11:591176. doi:10.3389/fimmu.2020.591176
   PubMed Web of Science ®Google Scholar
• Braun J, Kiltz U, Baraliakos X Emerging biological therapies in spondyloarthritides with focus on axial spondyloarthritis Expert Opin Biol Ther In press 2022
   Google Scholar